一名转移性非小细胞肺癌患者化疗后吉非替尼疗效的恢复

Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.

作者信息

Li Xiao-Dong, Geng Yi-Ting, Wu Chang-Ping, Shen Hua, Sun Jing, Shu Yong-Qian, Yin Yong-Mei

机构信息

Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

出版信息

Onkologie. 2010;33(8-9):466-9. doi: 10.1159/000319109. Epub 2010 Jul 27.

DOI:10.1159/000319109

PMID:20838064

Abstract

BACKGROUND

Gefitinib has shown evidence of antitumor activity in advanced non-small cell lung cancer (NSCLC).

CASE REPORT

A female Asian nonsmoker with adenocarcinoma was given gefitinib as first-line treatment with significant efficacy. However, after approximately 1.5 years, progression occurred. She then received chemotherapy (pemetrexed/carboplatin) until progression, followed by treatment with gefitinib to which the patient responded a second time. After progression, treatment with chemotherapy (docetaxel/cisplatin) was instituted and again followed by gefitinib. A recent positron emission tomography/computed tomography (PET/CT) scan showed complete remission under gefitinib.

CONCLUSIONS

This case report indicates that resistance to gefitinib in NSCLC can be reversed after chemotherapy. Thus, re-exposure to gefitinib may be justified in selected cases.

摘要

背景

吉非替尼已显示出对晚期非小细胞肺癌（NSCLC）具有抗肿瘤活性的证据。

病例报告

一名患有腺癌的亚洲非吸烟女性接受吉非替尼作为一线治疗，疗效显著。然而，大约1.5年后出现疾病进展。随后她接受化疗（培美曲塞/卡铂）直至疾病进展，之后再次接受吉非替尼治疗，患者再次出现反应。疾病进展后，开始使用化疗（多西他赛/顺铂）治疗，之后再次使用吉非替尼。最近的正电子发射断层扫描/计算机断层扫描（PET/CT）显示在吉非替尼治疗下完全缓解。